Abstract:Background & aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH), is increasing. Individuals with NASH often develop liver fibrosis and advanced liver fibrosis is the main determinant of mortality in individuals with NASH. We and others have reported that STAT3 contributes to liver fibrosis and hepatocellular carcinoma in mice. Methods: Here, we explored whether STAT3 activation in hepatocyte and non-hepatocyte areas, measured by phospho-STAT3 (pSTAT3), is associated with liver fibrosis progression in 133 patients with NAFLD. We further characterized the molecular and cellular determinants of STAT3 activation by integrating spatial distribution and transcriptomic changes in fibrotic NAFLD livers.Results: pSTAT3 scores in non-hepatocyte areas progressively increased with fibrosis severity (r = 0.53, p <0.001). Correlation analyses between pSTAT3 scores and expression of 1,540 immune- and cancer-associated genes revealed a large effect of STAT3 activation on gene expression changes in non-hepatocyte areas and confirmed a major role for STAT3 activation in fibrogenesis. Digital spatial transcriptomic profiling was also performed on 13 regions selected in hepatocyte and non-hepatocyte areas from four NAFLD liver biopsies with advanced fibrosis, using a customized panel of markers including pSTAT3, PanCK+CK8/18, and CD45. The regions were further segmented based on positive or negative pSTAT3 staining. Cell deconvolution analysis revealed that activated STAT3 was enriched in hepatic progenitor cells (HPCs) and sinusoidal endothelial cells. Regression of liver fibrosis upon STAT3 inhibition in mice with NASH resulted in a reduction of HPCs, demonstrating a direct role for STAT3 in HPC expansion. Conclusion: Increased understanding of the spatial dependence of STAT3 signaling in NASH and liver fibrosis progression could lead to novel targeted treatment approaches. Impact and implications: Advanced liver fibrosis is the main determinant of mortality in patients with NASH. This study showed using liver biopsies from 133 patients with NAFLD, that STAT3 activation in non-hepatocyte areas is strongly associated with fibrosis severity, inflammation, and progression to NASH. STAT3 activation was enriched in hepatic progenitor cells (HPCs) and sinusoidal endothelial cells (SECs), as determined by innovative technologies interrogating the spatial distribution of pSTAT3. Finally, STAT3 inhibition in mice resulted in reduced liver fibrosis and depletion of HPCs, suggesting that STAT3 activation in HPCs contributes to their expansion and fibrogenesis in NAFLD.

Quantitative Proteomic analysis on Activated Hepatic Stellate Cells reversion Reveal STAT1 as a key regulator between Liver Fibrosis and recovery

SILAC‐based Quantitative Proteomic Analysis of Secretome Between Activated and Reverted Hepatic Stellate Cells

In vitro reversion of activated primary human hepatic stellate cells

Single-cell Transcriptomics of Hepatic Stellate Cells Uncover Crucial Pathways and Key Regulators Involved in Non-Alcoholic Steatohepatitis

HMGB1-induced Autophagy Facilitates Hepatic Stellate Cells Activation: a New Pathway in Liver Fibrosis

Clearance of Activated Stellate Cells for Hepatic Fibrosis Regression: Molecular Basis and Translational Potential

Comparative Proteomic Analysis of Rat Hepatic Stellate Cell Activation: a Comprehensive View and Suppressed Immune Response.

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

In vitro inhibition of hepatic stellate cell activation by the autophagy-related lipid droplet protein ATG2A

Modulation of hepatic stellate cells and reversibility of hepatic fibrosis.

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis

Unraveling the Activation Process and Core Driver Genes of HSCs During Cirrhosis by Single-Cell Transcriptome.

Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures

System analysis based on weighted gene co-expression analysis identifies SOX7 as a novel regulator of hepatic stellate cell activation and liver fibrosis

Alteration of Protein Glycosylation in Human Hepatic Stellate Cells Activated with Transforming Growth Factor-Β1.

Activation and Inhibition of Human HSCs and the Related Molecular Mechanisms

Alteration of N-glycoproteins/N-glycosites in Human Hepatic Stellate Cells Activated with Transforming Growth Factor-Β1.

Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis

Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease